Pressemeldungen

June 16, 2009

VIVALIS AND MERIAL EXTEND THEIR COLLABORATION BY SIGNING A NEW EB66® CELL LINE RESEARCH LICENSE AGREEMENT FOR 10 NEW VACCINES PRODUCTION.

May 5, 2009

OXFORD-EMERGENT TUBERCULOSIS CONSORTIUM SIGNS COMMERCIAL LICENSE AGREEMENT WITH VIVALIS TO EXPLORE PRODUCTION OF MVA85® TB VACCINE CANDIDATE USING EB66 CELL LINE

April 29, 2009

Significant 2009 first quarter revenue of €2.4 million Continued positive cash flow in first quarter: +€2.1 million Net cash at 31 March 2009: €24.8 million

April 27, 2009

VIVALIS ANNONCES THE FILING OF ITS SECOND ANNUAL REGISTRATION DOCUMENT

April 23, 2009

SAFC BIOSCIENCES® AND VIVALIS COLLABORATE TO OPTIMIZE CELL CULTURE MEDIA FOR VACCINES PRODUCTION

April 8, 2009

PARTICIPATION IN SMALLCAP EVENT 27 & 28 APRIL 2009 IN PARIS

March 31, 2009

2008: positive net income ¹ : Operating income: €8.9 million (+180%) Net income¹: €0.5 million 2009 targets: continuation of sustained growth Net cash at year-end 2009 > €20 million Financial visibility over the next 4 years

March 3, 2009

VIVALIS AND FORT DODGE ANIMAL HEALTH SIGN A COMMERCIAL LICENSE AGREEMENT TO USE THE EB66®CELL LINE FOR VIRAL VACCINES PRODUCTION.

February 17, 2009

VIVALIS AND BOEHRINGER INGELHEIM ANIMAL HEALTH SIGN A RESEARCH LICENSE AGREEMENT, WITH AN OPTION TO ENTER INTO A COMMERCIAL LICENSE AGREEMENT TO USE EB66® PLATFORM FOR VETERINARY VACCINES PRODUCTION

February 9, 2009

VIVALIS ACHIEVES SIGNIFICANT MILESTONES IN THE DEVELOPMENT OF HUMAN FLU VACCINES BASED ON THE EB66® CELL LINE

1
…
46
47
48
49
50
…
52